Synta Pharmaceuticals Corp. (SNTA)
Key points:
- A Phase 2b/3 trial for ganetespib in combination with docetaxel in 2nd-line advanced NSCLC patients is expected to initiate in Q2 of 2011. Results expected end of 2011 or early 2012.
- Phase 2b trial of elesclomol in NSCLC expected to begin in Q2 2011.
- Approved for funding of up to $1 million from U.S. Department of Defense for pre-clinical development of VDA in prostate cancer.
- As of December 31, 2010, the Company had $51.0 million in cash, enough to carry operations into 2012.
The stock is at a strong fib support at these levels. It might be seen as a great buy between $4.11 to $4.7. Watch for these supports for some great buying opportunities.
Current pps: $4.68
Link to chart: link
Link to google finance: link
Link to latest headlines: link
Company website: link
Shares outstanding: 40.5M
Float: 25.4M
*Please do your own research before buying any stock listed here.
>> Subscribe to our posts.
